Sorafenib (BAY 43-9006)

A niacinamide and phenylurea derivative that inhibits multiple intracellular and cell surface kinases thought to be involved in ANGIOGENESIS, including RAF KINASES and VEGF RECEPTORS. It is used in the treatment of advanced RENAL CELL CARCINOMA and HEPATOCELLULAR CARCINOMA, and for treatment of THYROID CARCINOMA refractory to radioactive iodine therapy.

Also Known As:

BAY 43-9006; Nexavar; 4-(4-(3-(4-Chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxylic acid methyamide-4-methylbenzenesulfonate; BAY 545-9085; BAY-545-9085; BAY-673472; Sorafenib N-Oxide; Sorafenib Tosylate; BAY 43 9006; BAY 439006; BAY 545 9085; BAY 5459085; BAY 673472; BAY5459085; Sorafenib N Oxide; 2-Pyridinecarboxamide, 4-(4-((((4-chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-

Networked: 7404 relevant articles (1157 outcomes, 1886 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Kudo, Masatoshi: 109 articles (12/2023 - 06/2010)
2.	Cheng, Ann-Lii: 79 articles (02/2024 - 01/2009)
3.	Bruix, Jordi: 49 articles (04/2024 - 07/2008)
4.	Rimassa, Lorenza: 44 articles (02/2024 - 06/2009)
5.	Zhu, Andrew X: 43 articles (02/2024 - 01/2008)
6.	Ryoo, Baek-Yeol: 41 articles (02/2024 - 08/2010)
7.	Escudier, Bernard: 39 articles (01/2023 - 05/2006)
8.	Kim, Do Young: 38 articles (03/2024 - 09/2011)
9.	Qin, Shukui: 37 articles (06/2024 - 01/2009)
10.	Zhang, Wei: 37 articles (12/2023 - 08/2009)

Related Diseases

1.	Hepatocellular Carcinoma (Hepatoma) 02/01/2019 - "In light of constrained budgets and the need to fund efficient treatment options, this study set out to assess the cost-effectiveness of sorafenib as a first-line treatment of hepatocellular carcinoma (HCC) compared to best supportive care (BSC) from the military hospital perspective in Egypt. " 07/01/2013 - "The aim of this study was to evaluate the efficacy of sorafenib, compared to best supportive care (BSC), in two cohorts of patients which presented with hepatocellular carcinoma (HCC) recurrence after LT. " 01/01/2024 - "For advanced hepatocellular carcinoma (HCC), the best second-line treatment after first-line treatment with sorafenib is unclear. " 05/01/2022 - "Sorafenib is effective in treating hepatoma, but most patients develop resistance to it. " 03/01/2021 - "Hepatocellular carcinoma treatment with Sorafenib: A remarkable case of eight-years remission without significant toxicity."
2.	Neoplasms (Cancer) 12/18/2016 - "It is now recognized that the criteria (European Association of the Study of the Liver criteria, modified response evaluation criteria in solid tumors) based on contrast enhanced techniques (computed tomography scan, magnetic resonance imaging) aimed to assess the evolution of the viable part of the tumor (hypervascularized on arterial phase) are of major interest to determine the efficacy of sorafenib and of most antiangiogenic drugs in patients with HCC. " 07/01/2023 - "Results revealed that among the studied compounds, 4b exhibited the most pronounced cytotoxicity against cancer cells, surpassing even the efficacy of sorafenib. " 01/01/2022 - "Most importantly, the in vivo anti-tumor efficacy of DSF/Cu and sorafenib was tested using orthotopic HCC xenografts in mice. " 09/24/2020 - "However, the efficacy of sorafenib has become very limited because most tumors have developed resistance to this drug. " 01/01/2013 - "Collectively, these findings provide the first evidence that sorafenib inhibits the EMT process through an epigenetic mechanism, which holds enormous promise for identifying novel epigenetic candidate diagnostic markers and drug targets for the treatment of human malignancies."
3.	Renal Cell Carcinoma (Grawitz Tumor) 02/01/2013 - "Sorafenib has proven efficacy in metastatic renal cell carcinoma (mRCC). " 06/01/2007 - "These findings are consistent with other clinical results from this trial of advanced renal cell carcinoma patients treated with sorafenib, which included significantly greater progression-free survival and low risk for treatment limited toxicities." 12/21/2011 - "High dose intermittent sorafenib shows improved efficacy over conventional continuous dose in renal cell carcinoma." 03/01/2006 - "Based on the significant improvement in progression-free survival, sorafenib received Food and Drug Administration approval in December 2005 for the treatment of renal cell carcinoma. " 12/01/2016 - "Sorafenib, an oral multikinase inhibitor, has anti-proliferative and anti-angiogenic activities and is therapeutically effective against renal cell carcinoma (RCC). "
4.	Liver Neoplasms (Liver Cancer) 09/15/2023 - "Sorafenib is an important first-line treatment option for liver cancer due to its well-characterized safety profile. " 03/01/2024 - "Additionally, EGFR was activated in liver cancer cells after sorafenib treatment, and SERPINE2 knockdown-induced EGFR downregulation significantly enhanced the therapeutic efficacy of sorafenib against liver cancer. " 01/01/2024 - "Sorafenib is currently the first-line treatment for patients with advanced liver cancer, but its therapeutic efficacy declines significantly after a few months of treatment. " 08/01/2010 - "There is a better efficacy of Nexavar in treatment of liver cancer in the patients who had Ki-67-positive expression and high MVD count." 01/01/2019 - "The current study aimed to investigate the therapeutic efficacy of sorafenib against primary liver cancer (PLC). "
5.	Neoplasm Metastasis (Metastasis) 10/01/2017 - "RSR remained extremely poor with no significant improvement for advanced stage HCC who had vascular invasion (P=0.37) or distant metastasis (P=0.10), respectively for pre and post sorafenib era in each category. " 12/10/2009 - "In addition, sorafenib treatment dramatically reduced tumour volume of OS xenografts and lung metastasis in SCID mice. " 09/01/2013 - "Sorafenib is a molecularly targeted agent that has been proven effective for treating advanced HCC with extrahepatic metastasis. " 12/01/2009 - "Sorafenib was significantly less effective in patients with bone metastases. " 02/01/2021 - "The superior efficacy of sorafenib in the LT group was corroborated in multiple subgroup analyses stratified by metastasis, effective sorafenib maintenance dose, or Child-Turcotte-Pugh class A. "

Related Drugs and Biologics

1.	Sunitinib (Sutent)
2.	Tyrosine Kinase Inhibitors
3.	lenvatinib
4.	Bevacizumab (Avastin)
5.	Phosphotransferases (Kinase)
6.	regorafenib
7.	Everolimus
8.	atezolizumab
9.	Sorafenib (BAY 43-9006)
10.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)
3.	Liver Transplantation
4.	Radiotherapy
5.	Radiofrequency Ablation